Skip to main content

Table 3 Costs (2011 US$) and utilities input in the model

From: Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China

Parameter

Base-case (range)

Source/comment

Antiviral drug costs

  

Lamivudine (100 mg)

2.07(1.86-2.27)

Local charge

Adefovir (10 mg)

2.31 (2.15-3.08)

Local charge

Entecavir (1000 mg)

10.20 (8–10.2)

Local charge

Tenofovir (300 mg)

6.00 (4.62-7.69)

The price and range were assumed

Annual health state costs

  

Lamivudine-resistant CHB

138.7(104.62-209.23)

Assumed similar to naïve CHB[5]

Multi-resistant CHB

138.7(104.62-209.23)

Assumed similar to lamivudine-resistant CHB[5]

Virological response

138.7(104.62-209.23)

    [5]

Compensated cirrhosis

235.37(209.23-313.85)

    [5]

Decompensated cirrhosis

2122.55(1569.23-2615.38)

    [5]

HCC

5914.78(5230.77-10461.54)

    [5]

Liver transplantation

46152.94(44984.62-52307.69)

    [5]

Post-liver-transplantation

7691.63(7323.08-9415.38)

    [5]

Utilities (quality of life)

  

Lamivudine-resistant CHB

0.52(0.5-0.7)

    [34]

Multi-resistant CHB

0.52(0.5-0.7)

    [34]

Virological response

0.71(0.65-0.8)

    [34]

Compensated cirrhosis

0.57(0.5-0.7)

    [34]

Decompensated cirrhosis

0.26(0.2-0.35)

    [34]

HCC

0.31(0.24-0.38)

    [34]

Liver transplantation

0.7(0.54-0.76)

    [34]

  1. CHB, chronic hepatitis B.